Related Experiment Video
Updated: Apr 15, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Diagnosis and management of disseminated intravascular coagulation
1New York University School of Medicine, NY, USA.
Disseminated intravascular coagulation (defibrination syndrome, consumption coagulopathy) is a syndrome which may complicate a number of pathologic states. If clotting factors and platelets are "consumed" more rapidly than the patient can produce them, they may fall to levels which are not adequate for hemostasis. Thus, thrombosis with resulting necrosis and hemorrhage may occur simultaneously in the same patient. Local fibrinolysis (secondary fibrinolysis) may remove or partially remove intravascular thrombi, thus protecting against local tissue necrosis. Diagnosis of the fulminating syndrome is usually simple and depends upon a few relatively easy tests. If the syndrome is low grade, diagnosis is very difficult and may be impossible without sophisticated techniques. Differential diagnosis from coagulation defects secondary to liver disease is extremely difficult. Treatment in the fulminating case before intravascular thrombi can cause irreversible tissue damage is urgent. Treatment depends upon therapy of the underlying disease plus adequate heparinization. It may be necessary to administer platelets and blood fractions after heparinization. Corticosteroids are not contraindicated, particularly when the patient is heparinized. Epsilon-amino-caproic acid (EACA, Amicar) is contraindicated. This drug inhibits local fibrinolysis, which is protective to the patient.
Disseminated intravascular coagulation (defibrination syndrome, consumption coagulopathy) is a syndrome which may complicate a number of pathologic states. If clotting factors and platelets are "consumed" more rapidly than the patient can produce them, they may fall to levels which are not adequate for hemostasis. Thus, thrombosis with resulting necrosis and hemorrhage may occur simultaneously in the same patient. Local fibrinolysis (secondary fibrinolysis) may remove or partially remove intravascular thrombi, thus protecting against local tissue necrosis. Diagnosis of the fulminating syndrome is usually simple and depends upon a few relatively easy tests. If the syndrome is low grade, diagnosis is very difficult and may be impossible without sophisticated techniques. Differential diagnosis from coagulation defects secondary to liver disease is extremely difficult. Treatment in the fulminating case before intravascular thrombi can cause irreversible tissue damage is urgent. Treatment depends upon therapy of the underlying disease plus adequate heparinization. It may be necessary to administer platelets and blood fractions after heparinization. Corticosteroids are not contraindicated, particularly when the patient is heparinized. Epsilon-amino-caproic acid (EACA, Amicar) is contraindicated. This drug inhibits local fibrinolysis, which is protective to the patient.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

